Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis

ELIANE MANCUZO; Deborah Reis Estrella; Ricardo de Amorim Correa; Regina Tibana; Maria Raquel Soares; Carlos Alberto de Castro Pereira

doi:10.36141/svdld.v42i4.16938

Authors

ELIANE MANCUZO Universidade Federal de Minas Gerais
Deborah Reis Estrella
Ricardo de Amorim Correa
Regina Tibana
Maria Raquel Soares
Carlos Alberto de Castro Pereira

Keywords:

family history, pulmonary fibrosis, Interstitial lung disease

Abstract

Background: Familial pulmonary fibrosis (FPF) is defined as the occurrence of any interstitial lung disease (ILD) in two or more first- or second-degree relatives. Although the most frequently reported phenotype is idiopathic pulmonary fibrosis (IPF), other forms of ILD have been identified, such as fibrotic hypersensitivity pneumonitis (fHP). This study aims to explore survival between patients with IPF and fHP substratified by presence or absence of self-reported familial pulmonary fibrosis.

METHODS: Family history was acquired systematically, and patients were stratified by IPF or fHP according to specific guidelines. Clinical data on pulmonary function and imaging were collected during the first follow-up evaluation of patients. All cases were reviewed in multidisciplinary meetings. Other ILD diagnosis was excluded.

RESULTS: A total of 198 participants were included: 88 with IPF and 110 with fHP. In the IPF group, 36 had familial forms (F-IPF), and in the fHP group, 30 had familial fHP (F-fHP).

The variables age (hazard ratio [HR]: 1.03; 95% CI: 1.01 - 1.06; p = 0.01), FVC% (RR: 0.96; 95% CI: 0.94 - 0.98; p < 0.01), SpO2% (HR: 0.86; 95% CI: 0.76 - 0.97; p < 0.02), and family history of pulmonary fibrosis (HR: 1.79; 95% CI: 1.09 - 2.93; p = 0.02) were associated with mortality and were controlled before performing the survival curves. After adjusting for these four covariates, patients with F-IPF and F-fHP had similar survival curves, but worse than the homologous sporadic forms. The median survival for the FPF group, which included both F-IPF and F-fHP, was 46 months, compared to 75 months for the non-familial group (p < 0.05)

Conclusion: patients with familial presentations of IPF and fHP have significantly lower survival compared to patients with non-familial presentations of the same diseases. In clinical practice across many countries, genetic testing is not widely available, so family history should always be investigated.

References

- Borie R, Kannengiesser C, Antoniou K, Bonella F, Crestani B, Fabre A, et al. European Respiratory Society Statement on Familial Pulmonary Fibrosis. Eur Respir J. 2022;

- Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, et al. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019; 53(4):

- Cutting C, Bowman WS, Dao N, Pugashetti JV, Garcia CK, Oldham JM, et al. Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients with Interstitial Lung Disease. Chest. 2021;

- Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5): e44-e68.

- Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 202(3): e36-e69.

- Matias SLK, Pereira CaC, Soares MR, Fernandes FCV, Moreira MaC, Baptista FMA, et al. Relative incidence of interstitial lung diseases in Brazil. J Bras Pneumol. 2024; 50(1): e20230232.